Работы, цитирующие эту работу

Работ: 4

Работа: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

1. Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)

   Ashot Avagimyan, Mohammad Sheibani, А. И. Трофименко +15

   СтатьяDiabetes Treatment and ManagementInnovative medicine of Kuban2024Цитирований: 1

   ABIABI:AkademIndex/openalex/2024.article.001048

2. Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients

   Irina Balan, Tetyana Khayo, Sevara Sultanova +1

   Обзорная статьяDiabetes Treatment and ManagementCureus2021Цитирований: 0

   ABIABI:AkademIndex/openalex/2021.review-article.000026

3. Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022)

   И Е Чазова, Yu. V. Zhernakova, N. V. Blinova +19

   СтатьяCardiac Health and Mental HealthEurasian heart journal2022Цитирований: 0

   ABIABI:AkademIndex/openalex/2022.article.000532

4. Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022)

   И Е Чазова, Yu. V. Zhernakova, N. V. Blinova +20

   СтатьяCardiac Health and Mental HealthEurasian heart journal2022Цитирований: 0

   ABIABI:AkademIndex/openalex/2022.article.009850